Skip to content
etf.net

Launched

iShares Neuroscience and Healthcare ETF

IBRNNYSE ArcaC

$30.40−1.03 (−3.28%)

As of Oct 13, 2026, 3:20 PM

C44/ 100

Rank 10 of 17 in Biotech & Genomics

C44/100Rank 10 of 17inBiotech & Genomics
Intraday session: down, 4 prints from 31.43 to 30.40. Range 30.40 to 31.43. Use the arrow keys to read each point.30.6030.8031.0031.2010 AM12 PM2 PM4 PM
Expense ratio
0.47%
Fund size
$6M
1Y total return
+15.3%
Yield · Last 12 months
1.02%
Holdings
79
Avg volume · 30D
0M sh
NAV per share
$31.79
52W range
low $27.40high $43.01
Launched

The ETF.net IBRN Grade

Based on 5 of 6 pillars

C

Score 44 out of 100

Category
Biotech & Genomics⁠
Rank
10 of 17
Six-pillar profile for IBRN. Scores out of 100: Cost 56, Risk 28, Mission not scored, Tradability 28, Holdings 62, Durability 31. Strongest: Holdings (62). Weakest: Tradability (28). Based on 5 of 6 pillars.

Score 44 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    B56 out of 100
    Rank 7 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    D28 out of 100
    Rank 15 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D28 out of 100
    Rank 14 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    B62 out of 100
    Rank 8 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    D31 out of 100
    Rank 15 of 17

Our read on IBRN

ETF.net Research

CA healthcare fund with one obsession: the brain. IBRN tracks a global index of roughly 70 drugmakers and device companies working on neurological disease, a slice most sector funds bury inside hundreds of names.

Stated mandate

The fund seeks to track an index of global companies advancing research and treatment of neurological disorders, providing focused exposure to healthcare innovation related to brain health.

Why people hold it

  1. 01A rare single-theme cut of healthcare: brain-disease biopharma and medical devices held together, sourced globally rather than US-only.ishares.com
  2. 02At 0.47%, it undercuts the median expense ratio of its broad healthcare peer group, unusual for a narrow theme fund.
  3. 03Rules-based, not a stock picker: it follows a published NYSE FactSet neuro index, so the exposure you own is defined in advance.ishares.com

Worth knowing

  1. 01Small asset base and thin trading. Spreads can run wider than on the sector's heavyweights, and that cost lands on the buyer.
  2. 020.47% is several times what plain broad healthcare index funds like VHT and XLV charge. The theme is what you're paying for.
  3. 03Roughly 70 names in one research niche, live since 2022. Trial results at a few companies can swing it more than a whole-sector fund.

IBRN Holdings

As of Oct 12, 2026
Asset class
Stocks
Holdings
79
Top-10 weight
41%
Largest holding
BIIB5.0%

Geography

  • United States66.99%
  • Ireland4.92%
  • Netherlands4.36%
  • South Korea3.41%
  • Canada3.19%
  • Sweden3.11%
  • Denmark2.76%
  • Australia2.36%
  • Other countries (7)8.91%

Developed 79% · Emerging 21% of the foreign sleeve

The fund’s holdings, weight-ordered — page 1 of 6.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001BIIBBiogen4.96%1,396$315K324
002PTCTPtc Therapeutics4.53%4,446$288K130
003NBIXNeurocrine Biosciences4.44%1,981$282K247
004EWTXEdgewise Therapeutics4.40%7,148$279K68
005ALKSAlkermes4.28%6,686$272K150
006ARGXArgenx SE Adr3.89%299$247K70
007SRRKScholar Rock Holding3.70%5,565$235K80
008DNTHDianthus Therapeutics Inc3.69%2,848$235K84
009PRAXPraxis Precision Medicines3.58%875$227K104
010SUPNSupernus Pharmaceuticals3.56%5,299$226K118
011ACADAcadia Pharmaceuticals3.43%10,995$217K127
012DYNDyne Therapeutics3.32%12,682$211K85
013326030.KSSk Biopharmaceuticals Ltd3.25%3,810$206K41
014XENEXenon Pharmaceuticals2.96%5,158$188K67
015AXGNAxogen2.90%5,092$184K78

Showing 1–15 of 79 holdings

IBRN Performance

Launched Aug 24, 2022

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.
IBRN$11,527
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. IBRN $11,527. SPY $12,044. Use the arrow keys to read each point.$9,354$12,340$15,327Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for IBRN. Periods over one year show the average yearly return.
PeriodIBRN
Year to date−2.8%
1 month−16.0%
3 months−19.5%
1 year+15.3%
3 yearsper year+15.5%
5 yearsFund is under 5 years oldper year—
10 yearsFund is under 10 years oldper year—

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for IBRN
YearReturn barIBRN
2026 YTD−2.8%
2025+28.5%
2024−2.8%
2023+0.9%
2022+5.8%

History from Aug 26, 2022

IBRN in the news

Filtered to IBRN · Biotech & Genomics

IBRN Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
1.02%Last 12 months
Payout per share
$0.32Last 12 months
Last payment
$0.32 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2023–2026

One bar per payment. 4 payments from 2023 to 2026 YTD. Jun 7, 2023 $0.0082; Dec 20, 2023 $0.0063; Dec 17, 2024 $0.10; Dec 16, 2025 $0.32. Use the arrow keys to read each point.2023202420252026YTD
Ex-datePay dateAmount per share
Dec 16, 2025Dec 19, 2025$0.32
Dec 17, 2024Dec 20, 2024$0.10
Dec 20, 2023Dec 27, 2023$0.0063
Jun 7, 2023Jun 13, 2023$0.0082

IBRN Risk

How much the fund’s monthly returns vary, scaled to a year.
24.3%
Annualised · 36 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.59
vs 3-month T-bills · to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−35.4%
49 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.87
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

IBRN Cost

Expense ratio0.47%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

7 of the 17 Biotech & Genomics funds charge less.

IBRN costs $47.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.

Other funds in Biotech & Genomics

See others